Journal
CLINICAL LIPIDOLOGY
Volume 6, Issue 4, Pages 447-462Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/CLP.11.25
Keywords
drug interactions; fibrates; fish oil; guidelines; HIV-associated dyslipidemia; hypertriglyceridemia; niacin; statins
Categories
Funding
- ACTG
- National Institute of Allergy and Infectious Diseases [AI069532]
- Gilead
- GlaxoSmithKline
- Kowa
- Pfizer
- Tibotec
Ask authors/readers for more resources
Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available